These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23970362)

  • 1. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
    Chen W; Xiao Z; Zhao Y; Huang L; Du G
    Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
    Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
    Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
    Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
    Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
    Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
    Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
    Kovacs K; Scheithauer BW; Lombardero M; McLendon RE; Syro LV; Uribe H; Ortiz LD; Penagos LC
    Acta Neuropathol; 2008 Feb; 115(2):261-2. PubMed ID: 17926052
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
    Wang Y; Li J; Tohti M; Hu Y; Wang S; Li W; Lu Z; Ma C
    J Exp Clin Cancer Res; 2014 Jul; 33(1):56. PubMed ID: 25027022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
    Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J
    J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
    Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
    Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
    Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
    Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression.
    Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM
    J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.